Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer Europe OTC Drugs

Antibiotic OTC in UK

This article was originally published in The Tan Sheet

  • News

Executive Summary

Nottingham-based Optrex is launching Optrex Infected Eyes Eye Drops, the first nonprescription antibiotic eye drop for the treatment of conjunctivitis, expected to appear on UK pharmacy shelves by the end of June. Britain's Medicines & Healthcare products Regulatory Agency approved chloramphenicol 0.5 % eye drops for the treatment of acute bacterial conjunctivitis in adults and children aged two and older for pharmacy sale June 8. MHRA says it has weighed safety and bacterial resistance risks and is "convinced that the potential health benefits outweigh any risks to patients or to the community at large." Boots Pharmacy also will offer a private-label equivalent, according to MHRA...

Table

View full table

Topics

Tags:
Consumer Europe OTC Drugs
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS098294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By